Priceline Group Inc (NASDAQ:PCLN) Director Jeffery H. Boyd sold 3,000 shares of Priceline Group stock on the open market in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $1,228.00, for a total transaction of $3,684,000.00. Following the sale, the director now directly owns 194,125 shares of the company’s…
Earlier this month, Vivus Inc. (NASDAQ:VVUS) said it filed a patent-infringement lawsuit against Actavis PLC ( ACT ) alleging that the drug maker’s planned generic version of weight-loss drug Qsymia infringes its patents. VIVUS, Inc. (NASDAQ:VVUS) stock performance was 3.97% in last session and finished the day at $5.50. Traded volume was 4.47million shares in the last…
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) saw a significant decrease in short interest during the month of May. As of May 30th, there was short interest totalling 8,284,614 shares, a decrease of 15.5% from the May 15th total of 9,799,100 shares. Several analysts have recently commented on the stock. Analysts at Roth Capital downgraded shares of…
Geron Corporation (NASDAQ:GERN) on June 12 announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on the investigator-sponsored clinical trial of imetelstat in myelofibrosis (Myelofibrosis IST). The partial clinical hold was placed in March 2014 due to a safety signal of hepatotoxicity that was identified in clinical trials of…
Drugmaker Vivus Inc. (NASDAQ:VVUS) said Thursday it has filed a lawsuit against Actavis PLC and its affiliates in a New Jersey federal court over its bid with the U.S. Food and Drug Administration to sell a generic version of company’ prescription weight-loss drug Qsymia. VIVUS, Inc. (NASDAQ:VVUS) stock performance was -0.19% in last session and…
AstraZeneca Plc (ADR) (NYSE:AZN), in the headlines for spurning buyout offers from Pfizer Inc, aims to regain prominence in oncology with compelling trial results and a splashy exhibit booth at the world’s largest meeting of cancer doctors. AstraZeneca plc (ADR) (NYSE:AZN) stock performance was -0.83% in last session and finished the day at $72.76. Traded…
